Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6

Leukemia

Volumn 10, Issue 5, 1996, Pages 866-876

  Westendorf, J J ^a   Ahmann, G J ^a   Greipp, P R ^a   Witzig, T E ^a   Kyle, R A ^a   Lust, J A ^a   Jelinek, D F ^a  

^a MAYO CLINIC   (United States)

Author keywords

Autocrine; Cell lines; Cytokines; IL 6; Myeloma

Indexed keywords

ALPHA INTERFERON; CYTOKINE; DNA; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 3; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; MESSENGER RNA; ONCOSTATIN M; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BIOASSAY; CANCER CELL CULTURE; CASE REPORT; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; MYELOMA CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0029889061     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Mandelli F, Avvisati C, Tribalo M. Biology and treatment of multiple myeloma. Curr Opin Oncol 1992; 4: 73-86.
2. Matsuoka Y, Moore CE, Yagi Y, Pressman D. Production of free light chains of immunoglobulin by a hematopoetic cell line derived from a patient with multiple myeloma. Proc Soc Exp Biol Med 1967; 125: 1246-1250.
3. Nilsson K, Bennich H, Johansson SGO, Ponten J. Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin Exp Immunol 1970; 7: 477-489.
4. Nilsson K. Human B-lymphoid cell lines. Hum Cell 1992; 5: 25-41.
5. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988; 332: 83-85.
6. Bataille R, Jourdan M, Zhang XC, Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dycrasias. J Clin Invest 1989; 84: 2008-2011.
7. Klein B, Zhang XC, Jourdan M, Portier M, Bataille R. Interleukin-6 is a major myeloma cell growth factor in vitro and in vivo especially in patients with terminal disease. Curr Top Microbiol Immunol 1990; 166: 23-31.
8. Reibneggar G, Krainer M, Herold M, Ludwig H, Watcher H, Huber H. Predictive value of interleukin-6 and neopterin in patients with multiple myeloma. Cancer Res 1991; 51: 6250-6253.
9. Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Liautard I, Merlin M, Clement C, Morel-Fournier B, Lu ZY, Manoni P, Sany J, Bataille R. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood 1991; 78: 1198-1204.
10. Lu ZY, Zhang XG, Rodriguez C, Wijdenes J, Gu ZJ, Morel-Fournier B, Harousseau JL, Bataille R, Rossi JF, Klein B. Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells, Blood 1995; 85: 2521-2527.
11. Freund GG, Kulas DT, Mooney RA. Insulin and IGF-1 increase mitogenesis and glucose metabolism in the multiple myeloma cell line, RPMI 8226. J Immunol 1993; 151: 1811-1820.
12. Carter A, Merchav S, Silvian-Draxler I, Tatarsky I. The role of interleukin-1 and tumor necrosis factor alpha in human multiple myeloma. Br J Haematol 1990; 74: 424-431.
13. Hata H, Matsuzaki H, Takatsuki K. Autocrine growth by two cytokines, interleukin-6 and tumor necrosis factor alpha, in the myeloma cell line KHM-1A. Acta Haematol 1990; 83: 133-136.
14. Zhang XC, Gu JJ, Lu ZY, Yasukawa K, Yancopoulos GD, Turner K, Shoyab M, Taga T, Kishimoto T, Bataille R, Klein B. Ciliary neurotropic factor, interleukin 11, leukemia inhibitory factor, and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp130. J Exp Med 1994; 179: 1337-1342.
15. Nishimoto N, Ogata A, Shima Y, Tani Y, Ogawa H, Nakagawa M, Sugiyama H, Yoshizaki K, Kishimoto T. Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130. J Exp Med 1994; 179: 1343-1347.
16. Cozzolino F, Torcia M, Aldinucci D, Rubartelli A, Miliani A, Shaw AR, Lansdorp PM, Di Gugliemo R. Production of interleukin-1 by bone marrow myeloma cells. Blood 1989; 74: 380-387.
17. Bergui L, Schema M, Gaidano G, Riva M, Caligaris-Cappio F. Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma. J Exp Med 1989; 170: 613-618.
18. Zhang XG, Bataille R, Jourdan R, Saeland S, Banchereau J, Mannoni P, Klein B. Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood 1990; 76: 2599-2605.
19. Jourdan M, Zhang XG, Portier M, Boiran JM, Bataille R, Klein B. IFN-alpha induced autocrine production of IL-6 in myeloma cell lines. J Immunol 1991; 147: 4402-4407.
20. Cooper MR, Welander CE. Interferons in the treatment of multiple myeloma. Cancer 1987; 59: 594-600.
21. Seiden MV, Anderson KC. Multiple myeloma. Curr Opin Oncol 1994; 6: 41-49.
22. Johnson BH, Gomi M, Jakowlew SB, Moriwaki R, Thompson EB. Actions and interactions of glucocorticoids and transforming growth factor β on two clonally related human myeloma cell lines. Cell Growth Differ 1993; 4: 25-30.
23. Portier M, Zhang X, Caron E, Lu ZY, Bataille R, Klein B. Gamma Interferon in multiple myeloma: inhibition of interleukin-6 (IL-6) dependent myeloma cell growth and downregulation of IL-6-receptor expression in vivo. Blood 1993; 81: 3076-3082.
24. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in multiple myeloma. Blood 1995; 85: 863-872.
25. Hitzler JK, Martinez-Valdez H, Bergsagel DB, Minden MD, Messner HA. Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advances stage of the disease. Blood 1991; 78: 1996-2004.
26. Goto H, Shimazaki C, Tatsumi T, Yamagata N, Fujita N, Tsuchiya M, Koishihara Y, Ohsugi Y, Nakagawa M. Establishment of a novel myeloma cell line KPMM2 carrying t(3;14) (q21;q32), which proliferates specifically in response to interleukin-6 through an autocrine mechanism. Leukemia 1995; 9: 711-718.
27. Jernberg-Wiklund H, Pettersson M, Carlsson A, Nilsson K. Increase in interleukin (IL-6) and IL-6 receptor expression in a human multiple myeloma cell line, U-266, during long-term in vitro culture and the development of a possible autocrine IL-6 loop. Leukemia 1992; 6: 310-318.
28. Schwab G, Siegall CB, Aarden LA, Neckers LM, Nordan RP. Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Blood 1991; 77: 587-593.
29. Ozaki S, Wolfenbarger D, deBram-Hart M, Kanangat S, Weiss DT, Solomon A. Characterization of a novel interleukin-6 autocrine-dependent human plasma cell line. Leukemia 1994; 8: 2207-2213.
30. Keller ET, Ershler WB. Effect of IL-6 receptor antisense oligodeoxynucleotide on in vitro proliferation of myeloma cells. J Immunol 1995; 154: 4091-4098.
31. Westendorf JJ, Ahmann GJ, Armitage RJ, Spriggs MK, Lust JA, Greipp PR, Katzmann JA, Jelinek DF. CD40 expression in malignant plasma cells: role in stimulation of autocrine IL-6 secretion by a human myeloma cell line. J Immunol 1994; 152: 117-128.
32. Urashima M, Chauhan D, Uchiyama H, Freeman GJ, Anderson KC. CD40 ligand triggered interleukin-6 secretion in multiple myeloma. Blood 1995; 85: 1903-1912.
33. Lust JA, Letendre L, Thibodeau SN. Marrow hypoplasia associated with a monoclonal CDS large granular lymphocyte proliferation: reversal with cyclophosphamide and prednisone. Am J Med 1989; 87: 214-217.
34. Anderson KC, Bates MP, Slaughenhoupt B, Schlossman SF, Nadler LM. A monoclonal antibody with reactivity restricted to normal and neoplastic plasma cells. J Immunol 1984; 132: 3172-3179.
35. Huang YW, Burrows FJ, Vitetta ES. Cytotoxicity of a novel anti-ICAM-1 immunotoxin on human myeloma cell lines. Hybridoma 1993; 12: 661-675.
36. Jelinek DF, Ahmann GJ, Greipp PR, Jalal SM, Westendorf JJ, Katzmann JA, Kyle RA, Lust JA. Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications. Cancer Res 1993; 53: 5320-5327.
37. Hamilton MS, Ball J, Bromidge E, Franklin IM. Surface antigen expression of human neoplastic plasma cells includes molecules associated with lymphocyte recirculation and adhesion. Br J Haematol 1991; 78: 60-65.
38. Kozbor D, Moretta A, Messner HA, Moretta L, Croce CM. Tp44 molecules involved in antigen-independent T cell activation are expressed on human plasma cells. J Immunol 1987; 138: 4128-4132.
39. Pellet-Deceunynck C, Bataille R, Robillard N, Harousseau JL, Rapp MJ, Juge-Morineau N, Wijdenes J, Amiot M. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood 1994; 84: 2597-2603.
40. Westendorf JJ, Ahmann GJ, Lust JA, Tschumper RC, Greipp PR, Katzmann JA, Jelinek DF. Molecular and biological role of CD40 in multiple myeloma. Curr Topics Microbiol Immunol 1994; 194: 63-72.
41. Shima Y, Nishimoto N, Ogata A, Fujii Y, Yoshizaki K, Kishimoto T. Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood 1995; 85: 757-764.
42. Westendorf JJ, Lammert JM, Jelinek DF. Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines. Blood 1995; 85: 3566-3576.
43. Navarro S, Debili N, Bernaudin JF, Vainchenker W, Doly J. Regulation of the expression of IL-6 in human monocytes. J Immunol 1989; 142: 4339-4345.
44. Freeman GJ, Freedman AS, Raninowe SN, Segil JM, Horowitz J, Rosen K, Whitman JF, Nadler LM. Interleukin 6 gene expression in normal and neoplastic B cells. J Clin Invest 1989; 83: 1512-1518.
45. Hata H, Xiao H, Petrucci MT, Woodliff J, Chang R, Epstein J. Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells. Blood 1993; 81: 3357-3364.
46. Akira S, Isshiki H, Sugita T, Tanabe O, Kinoshita S, Nishio Y, Nakajima T, Hirano T, Kishimoto T. A nuclear factor for IL-6 expression is a member of a C/EBP family. EMBO J 1990; 9: 1897-1906.
47. Chen-Kiang S, Hsu W, Natkunam Y, Zhang X. Nuclear signaling by interleukin-6. Curr Opin Immunol 1993; 5: 124-128.
48. Nakajima K, Wall R. Interleukin-6 signals activating junB and TIS11 gene transcription in a B-cell hybridoma. Mol Cell Biol 1991; 11: 1409-1418.
49. Hsu W, Kerppola TK, Chen PL, Curran T, Chen-Kiang S. Fos and jun repress transcription activation by NF-IL6 through association at the basic zipper region. Mol Cell Biol 1994; 14: 268-276.
50. Margulies L, Sehgal PB. Modulation of the human interleukin-6 promoter (IL-6) and transcription factor C/EBPβ (NF-IL6) activity by p53 species. J Biol Chem 1993; 268: 15096-15100.
51. Anderson KC, Jones RM, Morimoto C, Leavitt P, Barut BA. Response patterns of purified myeloma cell to hematopoietic growth factors. Blood 1989; 73: 1915-1924.
52. King MA, Nelson DS. Tumor cell heterogeneity in multiple myeloma: antigenic, morphologic, and functional studies of cells from blood and bone marrow. Blood 1989; 73: 1925-1935.